Angiotensin II type 1 receptor blocker reduces monocyte adhesion to endothelial cells in spontaneously hypertensive rats.

Monocyte adhesion to arterial endothelial cells is the initial step in atherosclerosis. Whereas angiotensin II is known to elicit leukocyte adhesion, it is not clear whether blockade of the angiotensin II receptor signaling reduces monocyte adhesion to endothelial cells beyond its antihypertensive action. This study compared the effect of two different antihypertensive drugs on monocyte adhesion to thoracic aorta endothelium in spontaneously hypertensive rats (SHR): the angiotensin II receptor blocker, valsartan (20 mg . kg(-1) . day(-1)) and the vasodilator, hydralazine (0.75 mg . kg(-1) . day(-1)). The effects were quantitated in vivo using an enface method that optimizes the observation of endothelial surfaces after immunohistochemical staining for CD68. Both agents significantly and comparably reduced blood pressure over 4-week treatment course. Both valsartan and hydralazine profoundly reduced monocyte adhesion compared with nontreated controls, with valsartan having a modestly more reductive effect. Both agents also reduced the intima and medial thickening with valsartan reducing the mean thickness modestly more than hydralazine. Our data confirms that the reduction of blood pressure is effective method to reduce monocyte adhesion. Also, our date demonstrates that valsartan has a modest beneficial effect on monocyte adhesion to endothelial cells and arterial intima-medial vessel thickening beyond its action as an antihypertensive agent.

[1]  H. Daida,et al.  Insulin and nateglinide reduce monocyte adhesion to endothelial cells in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. , 2006, Biochemical and biophysical research communications.

[2]  R. Kawamori,et al.  Repetitive Fluctuations in Blood Glucose Enhance Monocyte Adhesion to the Endothelium of Rat Thoracic Aorta , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[3]  A. Hall,et al.  Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox , 2006, Circulation.

[4]  R. Tsuyuki,et al.  Response to Tsuyuki and McDonald , 2006 .

[5]  C. Ferrario,et al.  Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. , 2006, The American journal of cardiology.

[6]  H. Daida,et al.  Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. , 2006, Biochemical and biophysical research communications.

[7]  R. Stahl,et al.  Angiotensin II-Induced Mononuclear Leukocyte Interactions with Arteriolar and Venular Endothelium Are Mediated by the Release of Different CC Chemokines1 , 2006, The Journal of Immunology.

[8]  H. Daida,et al.  Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta , 2005, Diabetologia.

[9]  S. Kjeldsen,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The value randomised trial☆ , 2004 .

[10]  J. Panés,et al.  Direct evidence of leukocyte adhesion in arterioles by angiotensin II. , 2004, Blood.

[11]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[12]  R. Kawamori,et al.  A new En face method is useful to quantitate endothelial damage in vivo. , 2003, Biochemical and biophysical research communications.

[13]  A. Brasier,et al.  Vascular inflammation and the renin-angiotensin system. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[15]  P. Ridker,et al.  Novel clinical markers of vascular wall inflammation. , 2001, Circulation research.

[16]  P. Ridker,et al.  Blood Pressure and Inflammation in Apparently Healthy Men , 2001, Hypertension.

[17]  P. López-Jaramillo,et al.  Is C-reactive protein an independent risk factor for essential hypertension? , 2001, Journal of hypertension.

[18]  V. Dzau.  Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. , 2001, Hypertension.

[19]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[20]  R. Alexander,et al.  Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. , 1998, Circulation research.

[21]  E. Porteri,et al.  Effects of losartan and enalapril on small artery structure in hypertensive rats. , 1998, Hypertension.

[22]  J. Egido,et al.  Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. , 1997, Circulation.

[23]  M. Alderman.  Plasma renin activity and coronary heart disease: are they related? , 1995, Current opinion in nephrology and hypertension.

[24]  A. Nagaoka,et al.  Comparison of various genetic hypertensive rat strains. , 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[25]  K. Okamoto,et al.  Development of a strain of spontaneously hypertensive rats. , 1963, Japanese circulation journal.

[26]  R. Tsuyuki,et al.  Angiotensin receptor blockers do not increase risk of myocardial infarction. , 2006, Circulation.

[27]  L. Ghiadoni,et al.  Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. , 2000, Hypertension.